scholarly journals WITHDRAWN: Analysis of papillary thyroid carcinoma as the second primary tumor after definitive radiotherapy

Oncotarget ◽  
2018 ◽  
Vol 0 (0) ◽  
Author(s):  
Kai Qian ◽  
Kai Qian ◽  
Kai Guo ◽  
Kai Guo ◽  
Lu Di ◽  
...  



2020 ◽  
Vol 13 (1) ◽  
pp. 105-112 ◽  
Author(s):  
Gai Yamashita ◽  
Takahito Kondo ◽  
Akira Okimura ◽  
Munehide Nakatsugawa ◽  
Hiroshi Hirano ◽  
...  

Herein, we report a case of an occult thyroid cancer that was not detected as a primary tumor on preoperative ultrasonography or postoperative pathological examination, although a diagnosis of papillary thyroid carcinoma metastasis was made owing to the presence of a mass in the right upper neck. Needle biopsy of the mass in the right upper neck revealed positive results for thyroglobulin and TTF-1 on immunostaining, and a papillary thyroid carcinoma was observed with papillary and follicular patterns. We suspected papillary thyroid carcinoma (T0N1bM0) or ectopic papillary thyroid carcinoma. Accordingly, we performed total thyroidectomy, central lymph node dissection, right lateral neck dissection, and resection of the superficial lobe of the right parotid. A postoperative pathological examination of 5-mm slices of the specimen revealed no primary tumor in the thyroid. However, a hyalinized image of the thyroid indicated that a micropapillary thyroid carcinoma might have spontaneously disappeared. As there was no normal thyroid tissue in the metastasis to the superior internal jugular lymph node, the tumor was unlikely to be an ectopic papillary thyroid carcinoma. Therefore, we made a diagnosis of a papillary thyroid carcinoma (pT0N1bM0). After surgery, we determined that the tumor belonged to a high-risk group of papillary thyroid carcinomas and a poor-prognosis group of symptomatic papillary thyroid microcarcinomas; accordingly, ablation was performed with 30 mCi iodine-131. There was no recurrence or metastasis 24 months after the first surgery.



2021 ◽  
Vol 233 (5) ◽  
pp. e39
Author(s):  
Heba Elassar ◽  
Jordan Reilly ◽  
Morta Lapkus ◽  
Jacquelyn Pastewski ◽  
Diane Studzinski ◽  
...  


Biomedicines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 179
Author(s):  
Young-Jae Ryu ◽  
Seong-Young Kwon ◽  
Soo-Young Lim ◽  
Yong-Min Na ◽  
Min-Ho Park

Skip lymph node (LN) metastases in papillary thyroid carcinoma (PTC) belong to N1b classification in the absence of central neck LN involvement. This study aimed to evaluate the predictive factors of skip metastases and their impact on recurrence in PTC patients with pN1b. A total of 334 PTC patients who underwent total thyroidectomy with LN dissection (central and lateral neck compartment) followed by radioactive iodine ablation were included. Patients with skip metastases tended to have a small primary tumor (≤1 cm) and single lateral neck level involvement. Tumor size ≤ 1 cm was an important predictive factor for skip metastases. Univariate analysis for recurrence showed that patients with a central LN ratio > 0.68, lateral LN ratio > 0.21, and stimulated thyroglobulin (Tg) levels > 7.3 ng/mL had shorter RFS (recurrence-free survival). The stimulated Tg level was associated with shorter RFS on multivariate analysis (>7.3 vs. ≤7.3 ng/mL; hazard ratio, 4.226; 95% confidence interval, 2.226−8.022; p < 0.001). Although patients with skip metastases tended to have a small primary tumor and lower burden of lateral neck LN involvement, there was no association between skip metastases and RFS in PTC with pN1b. Stimulated Tg level was a strong predictor of recurrence.



2020 ◽  
Vol 13 (1) ◽  
pp. 207-211
Author(s):  
Arwa Alsaud ◽  
Shehab Mohamed ◽  
Mohamed A. Yassin ◽  
Amr Ashour ◽  
Khaldun Obeidat ◽  
...  

Papillary thyroid carcinoma is the most common primary thyroid cancer. Most frequently treated with surgical resection, some cases require radioactive iodine (RAI) therapy. Studies have suggested that there is an increase in second primary malignancy after RAI therapy amongst thyroid cancer survivors including acute myeloid leukemia (AML) as an infrequent cancer related to RAI therapy; it has a higher relative risk ratio in patients on higher doses of radiation exposure. We would like to report a 30-year-old lady who was diagnosed with papillary thyroid carcinoma. She underwent total thyroidectomy and received a low-dose RAI 131I therapy at a dose of 150 mCi, after which she developed therapy-related AML. Here we would like to highlight the association of AML with low-dose RAI as an infrequent cause of a second primary tumor compared to high doses.



2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Mariko Tsukagoshi ◽  
Norifumi Harimoto ◽  
Kenichiro Araki ◽  
Norio Kubo ◽  
Akira Watanabe ◽  
...  


2011 ◽  
Vol 58 (4) ◽  
pp. 175-184
Author(s):  
Marisa Cañadas Garre ◽  
Martín López de la Torre Casares ◽  
Patricia Becerra Massare ◽  
Miguel Ángel López Nevot ◽  
Jesús Villar Del Moral ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document